Please assess the completion status of the following clinical trial:

Trial Title: 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Consent to participate in the study~2. Age 4-11 years old~3. Male or eligible female - Female subjects should not be enrolled if they are pregnant, lactating or plan to become pregnant during the time of study participation~4. Asthma diagnosis for at least 6 months~5. Ability to answer questions regarding asthma control and use a metered dose inhaler and DISKUS~6. A history of clinical varicella infection or recipient of a varicella vaccine in countries where the product label includes a warning regarding more serious chickenpox infections in patients using corticosteroids.~7. History of at least once occurrence of asthma exacerbation within the prior 12 months~8. Currently being treated for asthma and no change in asthma therapy for the last 4 weeks (Eligible subjects include: subjects with use of short-acting beta-agonist, leukotriene receptor antagonist, theophylline, or cromolyn whose asthma is not well-controlled; subjects on low-dose ICS monotherapy whose asthma is not well-controlled; subjects on low-dose ICS and one or more adjunctive therapy whose asthma is either controlled or not well-controlled asthma; subjects on medium-dose ICS monotherapy whose asthma is either controlled or not well-controlled; and subjects on medium-dose ICS and one or more adjunctive therapy whose asthma is well-controlled)~Exclusion Criteria:~1. History of life-threatening asthma~2. Unstable asthma~3. Current use of high-dose ICS or ICS/LABA therapy to treat asthma symptoms~4. Concurrent respiratory disease: Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, or other severe respiratory abnormalities other than asthma.~5. Respiratory infection~6. Subjects with only exercise-induced asthma~7. An asthma exacerbation within the last 4 weeks or more than 4 separate exacerbations in the last 12 months~8. Hospitalization for asthma within 4 weeks or more than 2 hospitalizations within the last 12 months~9. Other current evidence of clinically significant uncontrolled disease/conditions of any body or organ system~10. Neurological or psychiatric disease or history of drug or alcohol abuse of a subject or his/her guardian which in the opinion of the investigator could interfere with the subject's proper completion of the protocol requirements~11. Participation in an interventional study or used any investigational drug for any disease state within the last 30 days~12. Any adverse reaction including immediate or delayed hypersensitivity to any beta-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy, or vehicle contained within these medication~13. Severe hypersensitivity to cow's milk proteins~14. Administration of prescription or over the counter medications that would significantly affect the course of asthma, or interact with sympathomimetic amines such as: anti-IgE (omalizumab), anticonvulsants (barbiturates, hydantoins, carbamazepine); polycyclic antidepressants, beta-adrenergic blockers; phenothiazines, monoamine oxidase inhibitors, or diuretics~15. Potent cytochrome P450 3A4 (CYP3A4) inhibitors within the last 4 weeks (e.g., ritonavir, ketoconazole, itraconzole)~16. Affiliation with investigator's site, including a immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.~17. A Child in Care (CiC) is a child who has been placed under the control or protection of an agency, organisation, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- ADVAIR 100/50mcg (Type: EXPERIMENTAL): fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
- ADVAIR 250/50mcg (Type: EXPERIMENTAL): fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
- FLOVENT 100mcg (Type: ACTIVE_COMPARATOR): fluticasone propionate (100) twice daily (AM and PM) for 6 months
- FLOVENT 250mcg (Type: ACTIVE_COMPARATOR): fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).